News & Events

Events & Presentations

American Association for Cancer Research (AACR) 2023: A next generation TEAD inhibitor with refined isoform specificity for superior safety & efficacy

View Presentation →

Oppenheimer 33rd Annual Healthcare Conference

View Presentation →

American Association for Cancer Research (AACR) Special Conference: Targeting RAS

View Presentation →

34th EORTC-NCI-AACR Symposium

View Presentation →

Press Releases

Sporos BioDiscovery Presents Preclinical Data on Next-Generation TEAD Inhibitor, SPR1-0117, at the American Association for Cancer Research (AACR) Annual Meeting 2023

Read More →

Sporos BioDiscovery to Present Preclinical Findings on SPR1, a Next-Generation TEAD Inhibitor, at the American Association for Cancer Research (AACR) Annual Meeting 2023

Read More →

Sporos BioDiscovery to Present at the Oppenheimer 33rd Annual Healthcare Conference

Read More →

Sporos BioDiscovery Presents Preclinical Data on Differentiated TEAD Inhibitor Program, SPR1, at the 34th EORTC-NCI-AACR Symposium

Read More →

FDA Grants Fast Track Designation to Tvardi Therapeutics’ TTI-101 for Hepatocellular Carcinoma

Read More →

Tvardi Therapeutics’ TTI-101 Receives Orphan Drug Designation for Idiopathic Pulmonary Fibrosis

Read More →

Tvardi Therapeutics’ TTI-101 Receives Orphan Drug Designation for Hepatocellular Carcinoma

Read More →

Data Demonstrating Tvardi’s TTI-101 Overcomes Palbociclib Resistance in Metastatic Breast Cancer Models to be Presented at the 2022 Annual Meeting of the American Association for Cancer Research

Read More →

Nirogy Therapeutics Appoints Simon Pedder, Ph.D., as Chief Executive Officer

Read More →

Sporos Bioventures Announces Formation of Strategic Advisory Board

Read More →

Sporos Bioventures Appoints Dr. Rachel Humphrey to Board of Directors

Read More →

Sporos Bioventures Appoints Amit Rakhit, M.D. as Chief Executive Officer

Read More →

Tvardi Therapeutics Raises $74 Million in Series B Financing to Advance Clinical Programs

Read More →

Stellanova Therapeutics, Inc. Announces Closing of $15.5 Million Series A Financing

Read More →

Asylia Therapeutics, Inc. Announces Closing of $14.5 Million Series A Financing

Read More →

Sporos Launches with $38.1 Million Series A Financing

Read More →

Nirogy Therapeutics to Present at AACR Annual Meeting 2021

Read More →

JLABS @ TMC and Asylia Therapeutics on Navigating a Powerful Tool: The Human Immune System

Read More →

Nirogy Therapeutics Launches with $16.5 Million Series A Financing

Read More →

Tvardi Therapeutics Awarded “Most Promising” Company at the 2020 Texas Life Science Forum

Read More →

New Company Asylia Therapeutics Finalizes Exclusive Worldwide License Agreement

Read More →

Tvardi Therapeutics Announces Publication Demonstrating TTI-101 as a Therapeutic Option for Treatment-Resistant Breast Cancers

Read More →

Tvardi’s TTI-101 Receives $5 Million in Funding to Support Clinical Trials and Translational Research

Read More →

Asylia Therapeutics Moves into JLABS @TMC

Read More →

KRLD Radio Interview: Some Covid Survivors Face Long-Term Consequences

Read More →

CPRIT Awards $3 Million to Asylia Therapeutics

Read More →

Heat Shock Protein-70 (HSP70) is an Essential Component of Anti-Tumor Immunity

Read More →

Biotech on the Rise

Read More →
Scroll to Top